Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Update

Biorestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a large drop in short interest during the month of August. As of August 14th, there was short interest totaling 99,687 shares, a drop of 78.5% from the July 30th total of 463,966 shares. Based on an average trading volume of 298,477 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.5% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Monday. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BRTX. Citadel Advisors LLC bought a new stake in shares of Biorestorative Therapies in the 3rd quarter worth approximately $152,000. DRW Securities LLC bought a new position in shares of Biorestorative Therapies during the fourth quarter valued at approximately $55,000. Finally, Virtu Financial LLC raised its holdings in shares of Biorestorative Therapies by 102.4% during the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after acquiring an additional 12,319 shares in the last quarter. Hedge funds and other institutional investors own 69.38% of the company’s stock.

Biorestorative Therapies Trading Down 5.0%

Shares of BRTX stock traded down $0.01 during mid-day trading on Thursday, reaching $0.21. The stock had a trading volume of 330,607 shares, compared to its average volume of 7,592,761. The firm has a market capitalization of $5.25 million, a PE ratio of -0.19 and a beta of 0.79. The stock’s 50-day moving average price is $0.29 and its two-hundred day moving average price is $0.29. Biorestorative Therapies has a 52-week low of $0.16 and a 52-week high of $1.89.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.